Needham & Company Reiterates a 'Strong Buy' on Gilead Sciences (GILD)

April 21, 2010 7:41 AM EDT
Get Alerts GILD Hot Sheet
Price: $66.54 --0%

Rating Summary:
    26 Buy, 14 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 38 | Down: 18 | New: 7
Trade Now! 
Join SI Premium – FREE
Needham & Company reiterates a 'Strong Buy' on Gilead Sciences Inc. (Nasdaq: GILD), price target $55.

Needham analyst says, "Nevertheless, we note that the core fundamentals remain in place. Favorable changes to HIV diagnosis and treatment guidelines are the predominant factors in our opinion and remain in Gilead’s favor. Furthermore, news from J&J yesterday provided assurance that the rilpivirine combination program is on track for NDA submission in 3Q10 and Gilead announced last week that the Quad pill has now moved to Phase 3."

To see all the upgrades/downgrades on shares of GILD, visit our Analyst Ratings page.


You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Needham & Company